Literature DB >> 18758431

The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century.

Maneesh N Singh1, Pierre L Martin-Hirsch, Francis L Martin.   

Abstract

Tamoxifen is a selective oestrogen receptor modulator (SERM) with an established role in the treatment and chemoprevention of hormone-related breast cancer. It is also cardioprotective and increases bone mineral density. However, due to pleiotrophic ligand-receptor properties, its role in a variety of seemingly unrelated disorders, including multiple sclerosis, Parkinson's disease, Alzheimer's disease, systemic lupus erythematosus and urological cancers, has been investigated in many studies. The non-patented drug tamoxifen confers a significant advantage over newer drugs in being inexpensive and well-tolerated with a known side-effect profile. This review highlights the interaction of tamoxifen on oestrogen receptors (ERs) and assesses whether this agent continues to have future applications in a variety of clinical settings, both as a therapy in early and established disease and usage as a prophylactic in those at risk of debilitating conditions. Indeed, it may have as-yet-unknown benefit(s) in a variety of conditions, both as a prophylactic in those at high-risk and also as in novel therapeutic strategies in established disease. Future clinical studies may seek to establish the exact future role and efficacy for SERMs both in men and women. Perhaps a multi-functional SERM such as tamoxifen may be the aspirin of the 21(st) century.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18758431

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  8 in total

1.  Estrogen and P2 Purinergic Receptor Systems in Microglia: Therapeutic Targets for Neuroprotection.

Authors:  Jessica M Crain; Jyoti J Watters
Journal:  Open Drug Discov J       Date:  2010-01-01

2.  Nuclear receptor engineering based on novel structure activity relationships revealed by farnesyl pyrophosphate.

Authors:  Ritu Goyanka; Sharmistha Das; Herbert H Samuels; Timothy Cardozo
Journal:  Protein Eng Des Sel       Date:  2010-09-03       Impact factor: 1.650

3.  A role for Sp1 in transcriptional regulation of phosphatidylethanolamine N-methyltransferase in liver and 3T3-L1 adipocytes.

Authors:  Laura K Cole; Dennis E Vance
Journal:  J Biol Chem       Date:  2010-02-11       Impact factor: 5.157

4.  The growth-inhibition effect of tamoxifen in the combination chemotherapeutics on the human cholangiocarcinoma cell line QBC939.

Authors:  Zhi-Hua Liu; Yan-Ping He; Huanlong Qin
Journal:  Mol Biol Rep       Date:  2009-09-13       Impact factor: 2.316

5.  Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway.

Authors:  Chihua Wu; Jing Luo
Journal:  Med Sci Monit       Date:  2016-10-21

6.  Tamoxifen Prevents Peritendinous Adhesions: A Preliminary Report.

Authors:  Oguz Kayiran; Suphan Tunc; Guler Gamze Eren Ozcan; Neslihan Kaya; Derya Karabulut
Journal:  Biomed Res Int       Date:  2022-09-20       Impact factor: 3.246

7.  Inhibitory effects of tamoxifen and doxorubicin, alone and in combination, on the proliferation of the MG63 human osteosarcoma cell line.

Authors:  Zheng-Xiao Ouyang; Xian-An Li
Journal:  Oncol Lett       Date:  2013-07-24       Impact factor: 2.967

8.  Novel Carbonyl Analogs of Tamoxifen: Design, Synthesis, and Biological Evaluation.

Authors:  Konstantinos M Kasiotis; George Lambrinidis; Nikolas Fokialakis; Evangelia N Tzanetou; Emmanuel Mikros; Serkos A Haroutounian
Journal:  Front Chem       Date:  2017-09-26       Impact factor: 5.221

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.